ClinicalTrials.gg
CompletedNCT01457495Updated Jun 16, 2017

Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly

A Phase 2 interventional study of DTPa-HBV-IPV/Hib (Infanrix-hexa™) and DTPa-IPV/Hib (Infanrix-IPV/Hib™) in Hepatitis B, Diphtheria and Haemophilus Influenzae Type b (Hib), sponsored by GlaxoSmithKline. Completed. Open to participants aged 12 Weeks to 16 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-16.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
312
Allocation
Randomized
Ages
12 Weeks to 16 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B — none open to participants now, none under way, none of them phase 3. diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine · Hepatitis B.

Enrollment
10th of 16
312 · median 417
Started
1998
the only one that year
Phase 2
3 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
14 of 16
GlaxoSmithKline

Among the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B, this one is the 10th largest by enrollment, is the only one that started in 1998, is one of 3 in phase 2, and was the 9th registered.

Hepatitis B

1,048 studies on the registry are indexed under Hepatitis B; 140 are open to participants now.

Browse Hepatitis B studies →

Open to participants now

None of the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B is open now. The open studies under Hepatitis B, anywhere →

About diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 80 Hepatitis B studies recruiting now, 40 (50%) set no upper age limit and 35 (44%) stop at 75 or younger; 14 take children under 18; 20 take healthy volunteers.

This study: 12 Weeks to 16 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine in Hepatitis B as a file.
02

Study summary

This study will assess the immunogenicity of GlaxoSmithKline (GSK) Biologicals' (formerly SmithKline Beecham Biologicals') DTPa-HBV-IPV/Hib (Infanrix hexa™) vaccine compared to the separate administration of DTPa-HBV-IPV (Infanrix™ penta) and Hib (Hiberix™) vaccines administered at 3 and 5 months of age.

03

Conditions studied

  • Hepatitis B
  • Diphtheria
  • Haemophilus Influenzae Type b (Hib)
  • Poliomyelitis
  • Pertussis
  • Tetanus

Keywords

  • Infants
  • combined vaccine
  • DTPa-HBV-IPV/Hib
  • DTPa-IPV/Hib
  • safety
  • Immunogenicity
  • HBV
04

Who can participate

Ages eligible
12 Weeks to 16 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female between 12 and 16 weeks of age at the time of the first vaccination.
  • Free of obvious health problems as established by medical history and clinical examination before entering into the study.
  • Written obtained from the parents or guardians of the subject after they have been advised of the risks and benefits of the study in a language which they clearly understood, and before performance of any study procedure.

Exclusion criteria

Exclusion Criteria:

  • Use of any or non-registered drug or vaccine other than the study vaccine(s) during the study period or within 30 days preceding the first dose of study vaccine.
  • Administration of chronic or immune-modifying drugs during the study period.
  • Administration of a vaccine not foreseen by the study protocol during the period starting from one month before each dose and ending one month after each dose.
  • Previous vaccination against diphtheria, tetanus, pertussis, , polio and/or Hib diseases.
  • History of/or intercurrent diphtheria, tetanus, pertussis, hepatitis B, polio and/or Hib disease.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, including (HIV) infection.
  • History of allergic disease or reaction likely to be exacerbated by any component of the vaccine, including allergic reactions to neomycin and polymyxin B.
  • Major congenital defects or serious chronic illness.
  • Progressive neurological disorders.
  • Administration of immunoglobulins and/or any blood products since birth and during the study period.
  • Acute febrile illness at the time of planned vaccination.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
312 participants (actual)

Study arms

  • Experimental
    DTPa 1 Group

    Biological: DTPa-HBV-IPV/Hib (Infanrix-hexa™)

  • Active comparator
    DTPa 2 Group

    Biological: DTPa-IPV/Hib (Infanrix-IPV/Hib™) · Biological: HBV (Engerix™-B)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects with antibody titers equal to or greater than cut-off value.

    Time frame: One month after the 2nd dose of the primary vaccination course (month 3)

Secondary outcomes

  1. Immunogenicity with respect to components of the study vaccines in terms of number of seropositive subjects

    Time frame: One month after the 2nd dose (Month 3), before and one month after the 3rd dose of the primary vaccination course (Months 8 and 9)

  2. Immunogenicity with respect to components of the study vaccines in terms of antibody titers

    Time frame: One month after the 2nd dose (Month 3), before and one month after the 3rd dose of the primary vaccination course (Months 8 and 9)

  3. Immunogenicity with respect to components of the study vaccines in terms of number of subjects with a vaccine response

    Time frame: One month after the 3rd dose of the primary vaccination course (Month 9)

  4. Occurrence of solicited local symptoms

    Time frame: Within 4 days after each vaccination and overall

  5. Occurrence of solicited general symptoms

    Time frame: Within 4 days after each vaccination and overall

  6. Occurrence of unsolicited symptoms

    Time frame: Within 30 days after each vaccination, and overall

  7. Occurrence of serious AEs

    Time frame: Throughout the entire study (approximately 9 months per subject) up to and including 30 days post-vaccination

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1998, a primary completion of Sep 1999 and a completion of Sep 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2011
First posted
Oct 24, 2011
Start
Sep 1998
Primary completionActual
Sep 1999
CompletionActual
Sep 1999
Last update
Jun 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01457495
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Oct 24, 2011
Start date
Sep 1998
Primary completion
Sep 1999
Completion
Sep 1999
Last update
Jun 16, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine

Start the discussion